JP2024516712A - ＳＡＲＳ－ＣｏＶ－２感染症の治療のためのクロロフィル誘導体の使用 - Google Patents

ＳＡＲＳ－ＣｏＶ－２感染症の治療のためのクロロフィル誘導体の使用 Download PDF

Info

Publication number
JP2024516712A
JP2024516712A JP2023568213A JP2023568213A JP2024516712A JP 2024516712 A JP2024516712 A JP 2024516712A JP 2023568213 A JP2023568213 A JP 2023568213A JP 2023568213 A JP2023568213 A JP 2023568213A JP 2024516712 A JP2024516712 A JP 2024516712A
Authority
JP
Japan
Prior art keywords
pheophorbide
acceptable salt
subject
sars
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516712A5 (https=
Inventor
ズッコロ，ジョナサン
ジェイ． ズッコロ，アミール
ディー． ディケアコス，ジミー
フィンク，コルビー
エイ． デカバン，グレゴリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affinityimmuno Inc
Original Assignee
Affinityimmuno Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinityimmuno Inc filed Critical Affinityimmuno Inc
Publication of JP2024516712A publication Critical patent/JP2024516712A/ja
Publication of JP2024516712A5 publication Critical patent/JP2024516712A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023568213A 2021-05-05 2022-05-04 ＳＡＲＳ－ＣｏＶ－２感染症の治療のためのクロロフィル誘導体の使用 Pending JP2024516712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201568P 2021-05-05 2021-05-05
US63/201,568 2021-05-05
PCT/CA2022/050697 WO2022232930A1 (en) 2021-05-05 2022-05-04 Use of chlorophyll derivatives for the treatment of sars-cov-2 infection

Publications (2)

Publication Number Publication Date
JP2024516712A true JP2024516712A (ja) 2024-04-16
JP2024516712A5 JP2024516712A5 (https=) 2025-05-12

Family

ID=83931896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568213A Pending JP2024516712A (ja) 2021-05-05 2022-05-04 ＳＡＲＳ－ＣｏＶ－２感染症の治療のためのクロロフィル誘導体の使用

Country Status (5)

Country Link
US (1) US20240366564A1 (https=)
EP (1) EP4333839A4 (https=)
JP (1) JP2024516712A (https=)
CA (1) CA3215826A1 (https=)
WO (1) WO2022232930A1 (https=)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALTAYEB HISHAM ET AL: "Potential activity of a selected natural compounds on SARS-CoV-2 RNA-dependent-RNA polymerase, and b", RESEARCH SQUARE, JPN7026001461, 4 June 2020 (2020-06-04), ISSN: 0005834601 *
ARCHIVES OF VIROLOGY, vol. 163, JPN7026001463, 9 April 2018 (2018-04-09), pages 2099 - 2109, ISSN: 0005834603 *
JOURNAL OF NATURAL MEDICINES, vol. 65, JPN7026001465, 11 September 2010 (2010-09-11), pages 229 - 233, ISSN: 0005834605 *
MICROBIOLOGY AND IMMUNOLOGY, vol. 58, JPN7026001464, 18 January 2014 (2014-01-18), pages 188 - 194, ISSN: 0005834604 *
THOMAS MEUNIER ET AL: "A photoactivable natural product with broad antiviral activity against enveloped viruses including h", BIORXIV, JPN7026001462, 9 July 2021 (2021-07-09), ISSN: 0005834602 *
ZHANG HNG-JIE ET AL: "Natural Anti-HIV Agents. Part IV. Anti-HIV Constituents from Vatica c inereas", JOURNAL OF NATURAL PRODUCTS, vol. 66, JPN7026001466, 29 January 2003 (2003-01-29), pages 263 - 268, ISSN: 0005834606 *

Also Published As

Publication number Publication date
US20240366564A1 (en) 2024-11-07
WO2022232930A1 (en) 2022-11-10
EP4333839A1 (en) 2024-03-13
EP4333839A4 (en) 2025-03-19
CA3215826A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
Faisal et al. Alkaloids as potential antivirals. A comprehensive review
Ferraris et al. Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules
KR102489519B1 (ko) 급성 호흡기 바이러스 감염 치료용 항바이러스 면역 억제제
JP2008523153A (ja) 疾病の伝染を減少させる組成物及び方法
CN105636589B (zh) 脱氧野尻霉素衍生物及其使用方法
Serkedjieva et al. In vitro anti-influenza virus activity of the pavine alkaloid (-)-thalimonine isolated from Thalictrum simplex L
KR102828536B1 (ko) 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물
US11419847B2 (en) Pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants
Smee et al. Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents
WO2021216385A1 (en) Methods for the prophylaxis and treatment of covid and covid-19
Chakraborty et al. Fighting the flu: a brief review on anti-influenza agents
Hao et al. Kaempferol is a novel antiviral agent against channel catfish virus infection through blocking viral attachment and penetration in vitro
US20230293565A1 (en) Use of wnt/beta-catenin pathway inhibitors to block replication of sars-cov-2 and other pathogenic viruses
US9221874B2 (en) Antiviral peptides against influenza virus
JP2024516712A (ja) ＳＡＲＳ－ＣｏＶ－２感染症の治療のためのクロロフィル誘導体の使用
US20240100047A1 (en) Composition and method for treating covid-19
CN110305189B (zh) 一种寡肽及其衍生物和应用
US20260034203A1 (en) Compositions, kits, and methods of immunizing against viral infections
CN107286044B (zh) 一种能够抑制流感病毒pb2蛋白与rna帽结合的化合物
US20240307487A1 (en) Compositions of anti-viral peptides and/or compounds and methods of use thereof
US20230390235A1 (en) Therapeutic agent for covid-19
WO2008034832A1 (en) Compositions comprising a statin and caffeine for the treatment of viral infection
WO2022232337A2 (en) Composition and method for treating covid-19
Goc et al. Micronutrient combination inhibits two key steps of coronavirus
EA050727B1 (ru) Антивирусный препарат микробного происхождения, обладающий активностью в отношении вирусов гриппа и коронавирусов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407